New cancer clinical trial: Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Published on: June 01, 2018 at 12:00PM
Conditions:   Triple-Negative Breast Carcinoma;   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Prognostic Stage IV Breast Cancer AJCC v8
Interventions:   Drug: Olaparib;   Biological: Durvalumab
Sponsor:   OHSU Knight Cancer Institute
Recruiting
https://ift.tt/2LeJ84t